Sai Parenterals' Subsidiary Secures Major Renewal of Exclusive OTC Supply Agreement in Australia

<h1>Sai Parenterals' Subsidiary Secures Major Renewal of Exclusive OTC Supply Agreement in Australia</h1>

Sai Parenterals Limited has announced that its Australian subsidiary, Noumed Pharmaceuticals Pty Ltd, successfully renewed its long-term exclusive OTC Medicines Supply Agreement with one of Australia's leading pharmacy chains. This landmark renewal significantly strengthens Sai Parenterals' international footprint and cements the company's standing as a trusted strategic partner in the highly regulated Australian market.

The agreement, effective from July 1, 2026, is valued at AUD 202 Million (equivalent to INR 1300 crores), translating to approximately AUD 27 Million per annum. The deal spans an extended term of 7.5 years and includes a potential three-year extension option upon mutual consent.

The renewed contract goes beyond mere duration, establishing a framework for continuous growth. It targets the addition of 12 new products each year, ensuring that both the OTC portfolio and the overall contract value continue to expand throughout its tenure.

Operational Excellence and Strategic Value

The agreement solidifies Noumed's role as a preferred supplier in Australia. Noumed is entrusted with the entire product lifecycle, which includes manufacturing, product sourcing, TGA registrations, quality assurance, warehousing, and nationwide distribution. This oversight reflects the deep trust placed by Australia's largest pharmacy networks in the company’s regulatory and operational capabilities.

The multi-layered value delivered by this agreement includes locking in predictable, recurring revenues for 7.5 years (extendable to over a decade). For Sai Parenterals Limited, this represents enhanced credibility as an international pharmaceutical partner, improved utilization of manufacturing infrastructure, and stronger earnings visibility from the growing OTC business segment.

Executive Perspectives

Mr. Anil Kumar Karusala, Managing Director of Sai Parenterals Limited, stated that the renewal reflects the continued confidence shown by Australia's leading pharmacy groups. He added that the agreement provides a "leap pad to our future expansion into other highly regulated markets," confidentially generating sustainable and predictable revenues for stakeholders.

Mr. Mark Thulborne, CEO of Noumed Pharmaceuticals Pty Ltd, noted that the long tenure signifies their capability to build lasting customer relationships and ensure certainty in forecasted revenues. He emphasized that the renewal further strengthens Noumed's presence in the Australian pharmaceutical market as a reliable partner across the complete value chain.

About Sai Parenterals Limited

Established in 2001, Sai Parenteral's Limited is a global IP-led pharmaceutical formulations company with operations across India and Australia. The company operates manufacturing facilities in India for both injectables and oral dosage forms, and it also has an upcoming facility slated for oral dosage forms in Australia. With strong in-house R&D capabilities, Sai Parenterals serves as a trusted partner to customers in regulated and semi-regulated markets globally.

SAIPARENT Stock Price Movement​

Today, shares of Sai Parenterals Limited rallied, closing higher at ₹612.10 after gaining 4.93% in market activity. The stock reached a new 52-week high as it traded amidst significant volume of 790,579 shares today.